ArticleNeurology(R) neuroimmunology & neuroinflammation2021
Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS.
Open access · goldAbstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Donor-specific pathological features associate with genetic background, lesion type distribution, and clinical heterogeneity in multiple sclerosis.Acta neuropathologica · 2026Article
- Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- B-cell abundance in perivascular cuffs associates with local lesion activity in multiple sclerosis.Acta neuropathologica communications · 2026Article
- Perturbances in Both Circulating B and CD4European journal of immunology · 2025Article
- A focus on the normal-appearing white and gray matter within the multiple sclerosis brain: a link to smoldering progression.Acta neuropathologica · 2025Review
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS.European journal of neurology · 2025Article
- Plasma cells in and around the central nervous system.Frontiers in immunology · 2025Review
- Should We Consider Neurodegeneration by Itself or in a Triangulation with Neuroinflammation and Demyelination? The Example of Multiple Sclerosis and Beyond.International journal of molecular sciences · 2024Review
- Review
- Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions.Acta neuropathologica · 2024Article
- Twin study dissects CXCR3Med (New York, N.Y.) · 2024Article
- Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation.Nature communications · 2024Article
- Smouldering Lesion in MS: Microglia, Lymphocytes and Pathobiochemical Mechanisms.International journal of molecular sciences · 2023Review
- Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis.Nature reviews. Neurology · 2023Review
- Multiple sclerosis risk variants influence the peripheral B-cell compartment early in life in the general population.European journal of neurology · 2023Article
- Multiple sclerosis: 2023 update.Free neuropathology · 2023Article
- The contribution of neuropathology to multiple sclerosis research.European journal of neurology · 2022Review
- Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.JCI insight · 2022Article
- B cells in central nervous system disease: diversity, locations and pathophysiology.Nature reviews. Immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Nina L FransenFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-0958-7162
Brigit A de JongFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-7005-7008
Katharina HeßFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.
Tanja KuhlmannFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-0174-5042
Maria C J VincentenFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.
Jörg HamannFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.
Inge HuitingaFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-4878-8920
Joost SmoldersFrom the Department of Neuroimmunology (N.L.F., M.C.J.V. J.H., I.H., J.S.), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Department of Neurology and MS Center, Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit (B.A.J.), The Netherlands; Institute for Neuropathology (K.H., T.K.), University Hospital Münster, Münster, Germany; Department of Experimental Immunology (J.H.), Amsterdam Infection & Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; Swammerdam Institute for Life Sciences, University of Amsterdam (I.H.), The Netherlands; and MS Center ErasMS (J.S.), Departments of Neurology and Immunology, Erasmus Medical Center, Rotterdam, The Netherlands. j.j.f.m.smolders@erasmusmc.nl.ORCID 0000-0001-9766-8661
Erasmus MC · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether B-cell presence in brainstem and white matter (WM) lesions is associated with poorer pathological and clinical characteristics in advanced MS autopsy cases.
methodsAutopsy tissue of 140 MS and 24 control cases and biopsy tissue of 24 patients with MS were examined for CD20
resultsIn 34% of active and 71% of mixed active/inactive lesions, B cells were absent, which correlated with less pronounced meningeal B-cell infiltration (
conclusionsThe absence of B cells is associated with a favorable clinical and pathological profile. This finding may reflect extremes of a continuum of genetic or environmental constitution, but also a regression of WM humoral immunopathology in the natural course of advanced MS.
Indexed as
Severity of Illness IndexAdultAgedB-LymphocytesBrain StemCase-Control StudiesCohort StudiesFemaleHumansMaleMiddle AgedMultiple SclerosisOligoclonal BandsWhite MatterOligoclonal Bands
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.